Search Tufts Medicine

This trial has two parts. Part A, an initial non-randomized Safety Run-In Phase to confirm the safety and tolerability at the selected dose range level of BNT113 in combination with pembrolizumab. Part B, the Randomized Phase of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy to generate pivotal efficacy and safety data in the first line setting in patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing PD-L1 with CPS ≥1. Randomization will be stratified by PDL1 CPS <20 vs PD-L1 CPS ≥20, and prior chemotherapy (yes vs no).

Working closely together, our clinical teams care for patients from birth through their late teenage years.  At Tufts Medical Center in Boston, we strive to keep the children and adolescents of our community healthy by providing routine primary care as well as emergency care and day surgery. 

Originally founded in 1893, we are a 234-bed general hospital offering a wide range of services, including expert cardiac care, 24-hour emergency care, wound care management and maternity services with an on-site Level II Special Care Nursery. We are the only hospital in the area offering an emergency cardiac catheterization lab, a life-saving procedure to open blocked arteries and limit heart damage. We are supported by over 700 affiliated physicians and have access to advanced specialty care with our clinical affiliation with Tufts Medical Center. 

Managing treatment made easy

Tufts Medicine Specialty Pharmacy is here to help you manage your disease and the specialty medications used to treat it. We provide you with services beyond just filling your prescriptions. We will guide you through your treatment plan and work with you and your doctors to achieve the best possible treatment outcome. We use the most current treatment information for common conditions, diagnoses, diagnostic procedures and medical interventions to ensure safe and effective drug therapy.

This study seeks to obtain cancer and healthy tissue from women with metastatic ovarian cancer. The tissue will be used in a preclinical study to develop a multi-scale imaging probe that can better detect cancer metastases.

This study will examine whether gum/periodontal diseases prior to cancer therapy impacts cancer therapy side-effects, quality of life, and response to treatment.

We are doing a research study to test a technology called spectroscopy that uses a special light and computer to better “see” where cancer is during surgery. We want to see if it can make surgery for mouth and throat cancer more effective by letting the doctor know if there are any cancer cells left behind during surgery.

Approximately 230,000 women are diagnosed with invasive breast cancer and 60,000 women are diagnosed with ductal carcinoma in situ (DCIS) (breast cancer in the breast milk ducts) annually in the US. Most women choose to be treated with breast conserving surgery (BCS). The goal of BCS is to resect the tumor with a surrounding margin of tissue free of cancer, and to minimize the volume of tissue removed, thereby preserving the overall shape and appearance of the breast.

This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). 

The purpose of this study is to evaluate the safety and effectiveness of the Vanquish Water Vapor Ablation Device (“Vanquish”) in subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate cancer

The purpose of this study is to describe, under real-world conditions, the safety and effectiveness of larotrectinib in patients with locally advanced or metastatic TRK fusion cancer for whom a decision to treat with larotrectinib has been made before enrollment.

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival.

This study is being done to answer the following question: Can a patient’s life be extended by adding a type of radiation therapy called whole-brain radiation therapy that avoids the hippocampus to preserve memory plus the medication memantine that is FDA approved to treat dementia to the usual treatment?

This study aims to find out if adding Hippocampal-Avoidant Whole Brain Radiotherapy and memantine is better or worse than the usual approach for your brain cancer.

This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone [R-miniCHOP]) versus R-miniCHOP alone in treating patients 75 years or older with newly diagnosed diffuse large B cell lymphoma. R-miniCHOP includes a monoclonal antibody (a type of protein), called rituximab, which attaches to the lymphoma cells and may help the immune system kill these cells.

This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

The purpose of this study is to collect blood samples for the further development of the diagnostic test Elecsys® Anti TPO II (anti-thyroid peroxidase antibody). This updated test is to aid in the diagnosis of autoimmune thyroid diseases like Hashimoto thyroiditis or Graves’ disease. In blood of patients suffering from these diseases, antibodies like anti-TPO are generally elevated. In the This study, the patient's blood sample will be analyzed with the updated Elecsys® Anti-TPO II test.